1.14.17.1	diagnostics	genotype-controlled measurement of plasma DBH activity might be used as a potential biological marker of the response to trauma	684300	
1.14.17.1	drug development	inhibitors of enzyme DBH nepicastat and etamicastat are currently in clinical development for treatment of cocaine dependence	746431	
1.14.17.1	medicine	a -1021C/T polymorphism in human dopamine-beta-hydroxyase shows an correlation with fasting plasma glucose in association with hypertension. CC homozygotes show a steeper increase in probability of hypertension with FPG than T allele carriers	673952	
1.14.17.1	medicine	adequate dietary Cu is essential to support DBM function in vivo	702945	
1.14.17.1	medicine	ethanol causes concentration- and time-dependent increase in DBH gene transcription. Protein kinase A, mitogen-activated protein kinase/extracellular signal -regulated kinase kinase, and casein kinase II inhibitors block induction of dopamine beta-hydroxylase and a large subset of ethanol-responsive genes. Ethanol regulation of dopamine beta-hydroxylase requires a functional cAMP-response element and its binding protein and may require interaction of multiple kinase pathways. These studies may have implications for behavioral responses to ethanol or mechanisms underlying ethanol-related neurological disease	659260	
1.14.17.1	medicine	inhibitors of enzyme DBH nepicastat and etamicastat are currently in clinical development for treatment of cocaine dependence	746431	
1.14.17.1	medicine	simple photometric method in clinical chemistry for determining the DBH activity in human blood, which parallels the protein level, and the high interest in DBH activity in the blood in various diseases that affect central and peripheral catecholamine systems, such as DBH deficiency and pheochromocytoma	703268	
1.14.17.1	medicine	the antidepressant drug imipramine counteracts the chronic mild stress-induced reduction of plasma dopamine beta-hydroxylase activity	660336